Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00278330 | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 |
| NCT00003406 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer | completed | Phase 1 / Phase 2 | 30 | Cancer Treatment Centers of AmericaOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT01130662 | Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | University of KansasOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00651781 | Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | PETHEMA FoundationOTHER | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00823524 | Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer | completed | Phase 1 / Phase 2 | 47 | Asan Medical CenterOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00002980 | Decitabine in Treating Patients With Melanoma or Other Advanced Cancer | completed | Phase 1 | — | California Cancer ConsortiumNETWORK | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00005967 | Tipifarnib in Treating Patients With Advanced Hematologic Cancer | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00114257 | Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00095797 | XK469R in Treating Patients With Refractory Hematologic Cancer | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00316953 | Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00101296 | Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00003451 | Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00015834 | STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077181 | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005064 | PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005942 | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006213 | BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00087204 | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00003528 | Raltitrexed in Treating Children With Refractory Acute Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00053963 | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00098826 | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00012376 | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00112853 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 100 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00131989 | Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00004918 | Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00357708 | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT01270984 | Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects(Imatinib) | completed | Phase 1 | 30 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00861874 | A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 13 | University of RochesterOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00710528 | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 192 | Gilead SciencesINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00762632 | Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | Technical University of MunichOTHER | 1 | Aug 8, 2012 | clinicaltrials |
| NCT00038831 | Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | completed | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00569010 | Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00592046 | A Phase I Trial of ZIO-101 in Hematologic Cancers | completed | Phase 1 | 12 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 19, 2012 | clinicaltrials |
| NCT00004904 | Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Northwestern UniversityOTHER | 1 | Jun 4, 2012 | clinicaltrials |
| NCT00004232 | Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Northwestern UniversityOTHER | 1 | Jun 1, 2012 | clinicaltrials |
| NCT00081822 | Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia | completed | Phase 1 | 23 | University of Alabama at BirminghamOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00719836 | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies | completed | Phase 1 / Phase 2 | 76 | S*BIOINDUSTRY | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00745550 | A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis | completed | Phase 1 / Phase 2 | 55 | S*BIOINDUSTRY | 2 | Apr 20, 2012 | clinicaltrials |
| NCT00270881 | Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 33 | Keio UniversityOTHER | 1 | Apr 6, 2012 | clinicaltrials |
| NCT00981240 | Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes | completed | Phase 1 | 30 | SanofiINDUSTRY | 1 | Mar 27, 2012 | clinicaltrials |
| NCT00064311 | Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00080925 | T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 20 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00088231 | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | completed | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01374139 | Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects | completed | Phase 1 | 88 | PfizerINDUSTRY | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00089037 | Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 15, 2011 | clinicaltrials |
| NCT00538876 | Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML | completed | Phase 1 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 30, 2011 | clinicaltrials |
| NCT00926731 | Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) | completed | Phase 1 | 4 | AstraZenecaINDUSTRY | 2 | Jun 16, 2011 | clinicaltrials |
| NCT00337454 | Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan | completed | Phase 1 / Phase 2 | 48 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2013source: clinicaltrials